Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis

被引：0
|
作者：
Simpson, Eric [1 ]
Boguniewicz, Mark [2 ,3 ]
Eichenfield, Lawrence [4 ]
Gonzales, Mercedes E. [5 ]
Hebert, Adelaide A. [6 ]
Prajapati, Vimal H. [7 ,8 ]
Gooderham, Melinda [9 ,10 ]
Krupa, David [11 ]
Chu, David H. [11 ]
Higham, Robert C. [11 ]
Berk, David R. [11 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR USA
[2] Natl Jewish Hlth, Denver, CO USA
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Univ Calif San Diego, Radys Childrens Hosp San Diego, San Diego, CA USA
[5] Pediat Skin Res LLC, Miami, FL USA
[6] UT Hlth, McGovern Med Sch, Houston, TX USA
[7] Skin Hlth Wellness Ctr, Dermatol Res Inst & Prob Med Res, Calgary, AB, Canada
[8] Univ Calgary, Calgary, AB, Canada
[9] SKiN Ctr Dermatol, Prob Med Res, Peterborough, ON, Canada
[10] Queens Univ, Peterborough, ON, Canada
[11] Arcutis Biotherapeut Inc, Westlake Village, CA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
atopic dermatitis; efficacy; patient-reported outcomes; roflumilast cream; safety;
D O I：
10.1093/bjd/ljae266.022
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
641
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo- controlled, phase 3 study
    Paller, Amy S.
    Silverberg, Jonathan I.
    Simpson, Eric L.
    Cork, Michael J.
    Arkwright, Peter D.
    Chen, Zhen
    Bansal, Ashish
    Prescilla, Randy
    Wang, Zhixiao
    Marco, Ainara R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (01) : 116 - 126
  • [42] Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib
    Simpson, Eric L.
    Wollenberg, Andreas
    Bissonnette, Robert
    Silverberg, Jonathan, I
    Papacharalambous, Jocelyne
    Zhu, Linda
    Zhang, Weidong
    Beebe, Jean S.
    Vincent, Michael
    Peeva, Elena
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Chen, Linda
    Sikirica, Vanja
    Xenakis, Jason
    DERMATITIS, 2021, 32 (1S) : S53 - S61
  • [43] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
    Blauvelt, Andrew
    Gooderham, Melinda
    Bhatia, Neal
    Langley, Richard G.
    Schneider, Shannon
    Zoidis, John
    Kurbasic, Azra
    Armstrong, April
    Silverberg, Jonathan, I
    DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2499 - 2516
  • [44] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
    Andrew Blauvelt
    Melinda Gooderham
    Neal Bhatia
    Richard G. Langley
    Shannon Schneider
    John Zoidis
    Azra Kurbasic
    April Armstrong
    Jonathan I. Silverberg
    Dermatology and Therapy, 2022, 12 : 2499 - 2516
  • [45] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
    Simpson, Eric L.
    de Bruin-Weller, Marjolein S.
    Prajapati, Vimal H.
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Zeng, Jiewei
    Liu, Meng
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB60 - AB60
  • [46] Efficacy and safety of lebrikizumab at 16 weeks: pooled analyses from ADvocate1 and ADvocate2 phase III trials in patients with moderate-to-severe atopic dermatitis
    Warren, Richard B.
    Silverberg, Jonathan I.
    Guttman-Yassky, Emma
    Thaci, Diamant
    Irvine, Alan
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric L.
    Chu, Chia-Yu
    Liu, Zhuqing T.
    Lima, Renata Gontijo
    Pillai, Sreekumar
    Garcia Gil, Esther
    Seneschal, Julien
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [47] Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
    Silverberg, Jonathan I.
    Thyssen, Jacob P.
    Rosmarin, David
    Pink, Andrew E.
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Hu, Xiaofei
    Yang, Yang
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB7 - AB7
  • [48] Etrasimod, a novel, oral selective S1P receptor modulator, in adults with moderate-to-severe atopic dermatitis: Analysis of patient-reported outcomes and itch in a phase 2 trial
    Murrell, D. F.
    Guttman-Yassky, E.
    Bissonnette, R.
    Kircik, L.
    Selfridge, A.
    Liu, K.
    Ahluwalia, G.
    Silverberg, J. I.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 18 - 19
  • [49] Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
    Linda Stein Gold
    Javier Alonso-Llamazares
    Zoe D. Draelos
    Melinda J. Gooderham
    Steven E. Kempers
    Leon H. Kircik
    Mark G. Lebwohl
    Kim A. Papp
    David M. Pariser
    Darryl P. Toth
    Gil Yosipovitch
    Robert C. Higham
    Amy Feng
    David R. Berk
    American Journal of Clinical Dermatology, 2023, 24 : 305 - 313
  • [50] Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results from the phase 3 DELTA-1 and-2 studies
    Bissonnette, R.
    Worm, M.
    Warren, R. B.
    Agner, T.
    Gooderham, M.
    Schuttelaar, M. L.
    Baranowski, K.
    Plohberger, U.
    Soerensen, L.
    Schliemann, S.
    ALLERGOLOGIE, 2024, 47 (09)
12345